Instil Bio reported Q1 2026 financial results with a net loss of $4.2 million, cash position of $74.7 million, and is evaluating acquisition and in-licensing opportunities.
Key takeaways
Net loss per share improved to $0.62 from $4.32 in Q1 2025, driven by lower operating expenses.
Cash and marketable securities of $74.7 million expected to fund operations beyond 2027.
Company is actively evaluating acquisition and in-licensing opportunities to build pipeline.
Research and development expenses decreased to $0.7 million from $5.4 million year-over-year.
Restructuring and impairment charges fell to $1.0 million from $16.1 million in Q1 2025.
Non-GAAP net loss per share was $0.32, compared to $1.32 in the prior year period.